A biotechnology company can develop a promising therapy, achieve favorable clinical results, and still struggle to create the investment value its management and shareholders anticipated.
Why?
Because clinical progress and commercial value are connected—but they are not the same thing.
After 36 years in biopharmaceutical commercialization, including more than 20 product launches across specialty therapeutics, neuroscience, rare disease, and endocrinology, I have learned to approach clinical-stage assets from a different starting point.
What will make this asset valuable to investors today and to pharmaceutical partners in the future?
The answer requires more than understanding disease biology or estimating the number of patients who could potentially receive a treatment.
It requires understanding the market that therapy will actually enter.
The Market Two to Three Years From Now
For Phase 1 and Phase 2 biotechnology companies, today's treatment landscape is only the starting point.
By the time an investigational therapy reaches its next major development milestone, clinical guidelines may have changed. Competitors may have introduced new treatments. Physician preferences may have shifted. New evidence may have altered treatment pathways.
A market opportunity that appears attractive today may look very different in three years.
These developments should influence decisions about clinical differentiation, indication selection, development priorities, and capital allocation.
Consider several examples drawn from therapeutic areas and programs I have evaluated.
Epilepsy: Understanding How Treatment Decisions Are Made
The epilepsy market is not defined solely by the number of available antiseizure medications.
Understanding how neurologists select therapies, how treatment decisions evolve, and how International League Against Epilepsy (ILAE) guidance influences clinical practice is essential.
General neurologists and epilepsy specialists may approach treatment differently.
A company's development strategy should reflect those realities, the changing competitive environment, and the potential opportunities to alter established treatment patterns.
The important question is not simply whether a new drug can demonstrate efficacy.
It is whether the development program is building evidence that can change clinical decisions in the market the product will eventually enter.
Alzheimer's Disease: What Will Differentiate the Next Program?
Alzheimer's drug development illustrates the importance of evaluating clinical evidence and investment decisions together.
A published analysis identified 98 unique drug candidates that failed in Phase 2 or Phase 3 trials between 2004 and 2021.
These historical failures do not invalidate subsequent scientific advances, but they reinforce the importance of carefully selecting development strategies.
For companies pursuing amyloid-beta, tau, or alternative biological pathways, a central question remains:
What biomarker evidence will meaningfully differentiate the investigational treatment and strengthen the case for further investment?
Biomarker selection, patient populations, clinical outcomes, and the relationship between biological effects and meaningful patient benefit can all influence how investors and future partners evaluate an asset.
Schizophrenia: Differentiation Beyond Positive Symptoms
Schizophrenia already has established therapies, including inexpensive generic medications.
Demonstrating improvement in positive symptoms may establish clinical activity, but it does not automatically create a compelling commercial position.
Negative symptoms, cognitive impairment, treatment tolerability, and functional outcomes remain important considerations.
For an emerging therapy, the questions extend beyond its receptor targets or neurotransmitter pathways.
Will its mechanism and supporting clinical evidence translate into a meaningful difference in patient care—and one that physicians will recognize?
That distinction can shape development priorities and future investment value.
Anxiety Disorders: An Established Market With Unmet Needs
Anxiety disorders present another challenge for companies developing innovative therapies.
Multiple treatment options already exist, yet limitations involving treatment response, tolerability, onset of action, and long-term management remain.
An investigational therapy must establish which unmet need it intends to address and why the resulting clinical benefit would influence prescribing decisions.
A new mechanism alone is not a commercial strategy.
The investment case becomes stronger when the development program can establish a credible path toward clinically meaningful differentiation.
Rare Disease: Small Populations, Complex Markets
Rare-disease development often begins with compelling science and significant unmet medical need.
But clinical promise does not eliminate practical market constraints.
Patients may be geographically dispersed. Diagnosis may be delayed. Treatment may depend on specialized centers, hospital infrastructure, and complex reimbursement arrangements.
Competing clinical trials can also affect enrollment, while the requirements for delivering treatment may influence the realistically accessible patient population.
A prevalence estimate is not the same as a commercially reachable market.
Understanding that distinction early can influence indication priorities, clinical-development decisions, investor expectations, and future partnering opportunities.
From Clinical Development to Investment Value
These examples illustrate a common problem.
Biotechnology companies frequently make major development and capital-allocation decisions before fully evaluating the commercial circumstances that could determine an asset’s eventual value.
The objective is not to add unnecessary complexity to clinical trials or delay regulatory progress.
It is to identify which decisions and evidence requirements are most consequential while there is still an opportunity to act.
For a company with multiple assets or indications, the strongest scientific opportunity may not necessarily represent the strongest near-term investment opportunity.
Management must consider development costs, evidence requirements, competitive positioning, future market access, and the milestones most likely to create additional value.
Those decisions directly influence the investment narrative presented to venture capital firms, institutional investors, and potential pharmaceutical partners.
An Investor Presentation Must Connect Science to Value
An investor presentation should do more than summarize disease biology, clinical results, and projected market size.
It should communicate why the company's development choices are credible, how the therapy could distinguish itself, and which future milestones may strengthen its position.
This may include an independent portfolio assessment, realistic market evaluation, clinical differentiation analysis, and carefully selected perspectives from recognized clinical experts.
A verified key opinion leader's perspective on unmet need, limitations of existing treatment, or the practical realities of patient care can add valuable context.
The objective is not to manufacture enthusiasm.
It is to build an investment case that can withstand informed scrutiny.
Bringing Commercial Experience Upstream
Through PharmaKonsult, I work with clinical-stage biotechnology companies to examine assets and portfolios from the commercial endpoint backward.
My Investment & Asset Value Creation Assessment brings together portfolio priorities, future market conditions, physician and payer realities, clinical differentiation, and investor positioning.
The engagement can culminate in strategic recommendations and an investor-ready presentation connecting clinical development to a credible business opportunity.
This is not sales-force preparation.
It is an effort to help companies make better development decisions while those decisions can still influence investment and future licensing value.
FDA approval remains an essential milestone.
But the value of a biotechnology company is built through a series of decisions made long before approval.
The question is whether those decisions are creating an asset that investors will fund, physicians will prescribe, patients can access, and pharmaceutical partners will want to license.
Research reference
Kim CK et al. Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures. Journal of Alzheimer’s Disease. 2022;87(1):83–100. DOI: 10.3233/JAD-215699.
Joseph McCoy | Founder & Principal, PharmaKonsult | PharmaKonsult.com
